TEAM

CURRENT MEMBERS

Postdoctoral researchers

Picture1.jpg

Development of an animal-free strategy to detect cholestatic drugs

To be completed in 2023

Promoter: Mathieu Vinken

Dr. Pharm. Alanah Pieters

20191012_183818.jpg

Characterization of new mechanisms of cholestasis as the basis for animal-free prediction of drug-induced liver injury

To be completed in 2022

Promoter: Mathieu Vinken

Dr. Pharm. Bruna dos Santos Rodrigues

Foto.jpg

In vitro and in silico prediction of chemical-induced liver toxicity

To be completed in 2026

Promoter: Mathieu Vinken

Dr. M. Sci. Jian Jiang

Picture.png

Development of a new liver-based in vitro system to detect cholestatic chemicals

To be completed in 2024

Promoter: Mathieu Vinken

Dr. Pharm. Julen Sanz Serrano

Profile_Picture_Andrés_Tabernilla.jpg

In vitro testing of new inhibitors of Cx43 hemichannels and Panx1 channels

To be completed in 2024

Promoter: Mathieu Vinken

Dr. M. Sci. Andrés Tabernilla

Foto.jpg

In vivo testing of new inhibitors of Cx43 hemichannels and Panx1 channels

To be completed in 2024

Promoter: Mathieu Vinken

Dr. D.V.M. Prashant Kadam

Doctoral researchers

Emma Gustafson.jpg

Development and testing of a repeated dose toxicity ontology model for chemical risk assessment purposes: liver effects as a case study

To be defended in 2022

Promoters: Mathieu Vinken, Tamara Vanhaecke

M. Sci. Emma Arnesdotter

caufriez_Anne.jpg

Development and in vitro testing of new inhibitors of Cx32 hemichannels and Panx1 channels

To be defended in 2023

Promoters: Mathieu Vinken, Steven Ballet

M. Pharm. Sci. Anne Caufriez

Pharm. Axelle Cooreman.jpg

The role of connexins, pannexins and their channels in cholestasis

To be defended in 2022

Promoters: Mathieu Vinken, Pieter Annaert

Pharm. Axelle Cooreman

picture.jpg

Effects of microplastics on liver in vitro and in vivo

To be defended in 2025

Promoters: Mathieu Vinken, Lindsey Devisscher

M. Sci. Sybren De Boever

Pharm. Eva Gijbels.jpg

Characterization of new mechanisms of cholestasis as the basis for animal-free prediction of drug-induced liver injury

To be defended in 2021

Promoters: Mathieu Vinken, Lindsey Devisscher

Co-promoter: Tamara Vanhaecke

Pharm. Eva Gijbels

M. Sci Kaat Leroy.jpg

The role of connexins, pannexins and their channels in liver cancer

To be defended in 2022

Promoters: Mathieu Vinken, Bruno Cogliati

M. Sci. Kaat Leroy

Foto.jpeg

Effects of food supplements on liver in vitro and in vivo

To be defended in 2025

Promoters: Mathieu Vinken, Lindsey Devisscher

Pharm. Amy Maerten

IMG_6160 (2).jpg

The role of Cx43 hemichannels and Panx1 channels in liver cancer

To be defended in 2024 (University of São Paulo-Brazil)

Promoters: Bruno Cogliati, Mathieu Vinken

M. Sci. Cícero Júlio Silva Costa

Pharm. Raf Van Campenhout.jpg

Development of new inhibitors of Cx43 hemichannels and Panx1 channels as novel therapeutics for the treatment of liver disease

To be defended in 2022

Promoters: Mathieu Vinken, Nick Devoogdt, Serge Muyldermans

Co-promotor: Timo De Groof

Pharm. Raf Van Campenhout

Foto.jpg

In vitro detection of cholestatic chemicals

To be defended in 2025

Promoter: Mathieu Vinken

Pharm. Jonas van Ertvelde

Foto.jpg

In vitro detection of steatotic chemicals

To be defended in 2025

Promoters: Mathieu Vinken, Tamara Vanhaecke

Co-promotor: Joery De Kock

Pharm. Anouk Verhoeven

 

 

Technicians

thumbnail_0cd9919d-2635-4571-9609-af819b2dba37.jpg

Fien Haenen

PasfotoAL.jpg

 

 

Project manager

 

 

 

 

 

 

 

 

 

 

 

       

 

 

 

 

 

FORMER TEAM MEMBERS

profile photo JZ.jpg

Dr. Med. Sci. Julia Dominika Zajac

Arne Loosen

Dr. Vânia Vilas-Boas

M. Sci. Sara Crespo-Yanguas

Pharm. Michaël Maes

Pharm. Joost Willebrords

Miss Ana Rita Coelho Gomes

Miss Dinja De Win

Miss Tâmara Prandini

Miss Tineke Vanhalewyn

Miss Manon Wery

FINISHED POSTDOCTORAL PROJECTS

Role of connexin and pannexin (hemi)channels in liver cancer

Tereza Cristina da Silva: completed 31/03/2017

Promoters: Mathieu Vinken, Bruno Cogliati

Role of connexin and pannexin (hemi)channels in hepatitis

Isabel Veloso Alves Pereira: completed 31/03/2017

Promoters: Mathieu Vinken, Bruno Cogliati

Development of a primary hepatocyte spheroid culture system for the detection of chemical-induced cholestatic liver injury

Vânia Vilas-Boas: completed 31/12/2020

Promoter: Mathieu Vinken

 

 

FINISHED DOCTORAL PROJECTS

Evaluation of carcinogen-modified global gene expression profiles in liver-based in vitro models with focus on primary hepatocyte cultures

Tatyana Doktorova: defended 16/03/2012

Promoters: Mathieu Vinken, Tamara Vanhaecke, Vera Rogiers

 

Development of a differentiated hepatic in vitro system for long-term pharmaco-toxicological studies based on (epi)genetic modification of primary hepatocytes

Eva Ramboer: defended 15/10/2015

Promoters: Mathieu Vinken, Tamara Vanhaecke, Vera Rogiers

 

The role of connexins, pannexins and their channels in acute liver failure

Michaël Maes: defended 17/10/2017

Promoters: Mathieu Vinken, Bruno Cogliati

 

The role of connexins, pannexins and their channels in non-alcoholic steatohepatitis

Joost Willebrords: defended 29/01/2018

Promoters: Mathieu Vinken, Bruno Cogliati

 

The role of connexins, pannexins and their channels in liver fibrosis

Sara Crespo Yanguas: defended 25/10/2018

Promoters: Mathieu Vinken, Bruno Cogliati

 

Connexin43 hemichannels as druggable targets for future anti-seizure medication

Laura Walrave: defended 24/01/2019

Promoter: Ilse Smolders

Co-promoters: Mathieu Vinken, Luc Leybaert

© 2023 by InVitroTox Consulting.

Proudly created using Wix.com

  • LinkedIn Social Icon